Generate Q1 net loss widens to $61.7M, cash $516.6M post-IPO; pipeline advances

Generate Biomedicines, Inc.

2026-Q1 EPS reported -$1.07 revenue$7,224,000

Net loss $61.7M vs $44.3M YoY; revenue $7.2M (down 18% from $8.8M).
Cash & equivalents $516.6M, includes $369.3M IPO proceeds; runway into H1 2028.
GB-0895 (anti-TSLP) Phase 3 SOLAIRIA-1/2 ongoing in severe asthma; Phase 1b in COPD.
GB-4362 (MMAE neutralizer) FDA Fast Track; first patient dosing expected mid-2026.
GB-5267 (MUC16 armored CAR T with Roswell Park) first patient expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Generate Biomedicines, Inc. reported the first quarter ended March 31, 2026 results: revenue $7.2 million, net income Net loss was $61.7 million.

Period: the first quarter ended March 31, 2026
Revenue: $7.2 million
Net income: Net loss was $61.7 million
Result: reported results

Exact text from the filing

its operations into the first half of 2028. Generate expects to require additional capital to support long-term operations. Revenue for the quarter ended March 31, 2026, was $7.2 million, compared with $8.8 million for the same period in 2025. This revenue reflects developments in the ongoing Amgen and Novartis research programs. Research and development expenses

View on SEC.gov

15 earnings releases filed in the last 30 days. Browse all earnings releases →

Generate Biomedicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-209899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.